The Cochrane Collaboration do systematic reviews of the published scientific evidence - they look at all the information that is available.
This year, they looked at this issue:
The question asks about Crohn's disease, but they looked further - at IBD:
Inflammatory bowel disease (IBD) is comprised of two disorders: ulcerative colitis and Crohn’s disease. These disorders have both distinct and overlapping symptoms, but the underlying cause remains incompletely understood.
They only found two moderately small trials, and neither of them were able draw any strong conclusions about the safety or the effectiveness of the treatment.
Currently, there is insufficient evidence to allow any firm conclusions regarding the effectiveness and safety of helminths used to treat patients with IBD. The only information available relating to clinical improvement in patients with active ulcerative colitis comes from one small study. We do not know how safe helminths are when used in patients with ulcerative colitis and Crohn's disease.
So, as of January 2014, it was too early to say whether such a treatment is going to work or is going to be safe.
Just for completeness, Cochrane looked into Adalimumab (a.k.a. Humira) too:
The current evidence suggests that the TNF-alpha blocking agents infliximab, adalimumab, and certolizumab pegol are effective maintenance therapy in Crohn's disease. However, the use of these medications needs to be weighed against the potential risk of serious side effects, particularly infection.